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Background: The ultra-short course pre-seasonal allergy vaccine, containing appropriate 
allergoids with the adjuvant monophosphoryl lipid A (MPL), may be effective in treating 
allergic symptoms. 
Objective: To explore the timing of the immunological responses to the pre-seasonal allergy 
vaccine.
Methods: Four subcutaneous injections of the active product (Pollinex Quattro) were 
administered to 20 Parietaria-sensitive intermittent asthmatics (M/F: 12/8; age: 48 ± 10 years; 
FEV1% predicted: 108% ± 12%) during the 6 weeks prior to the start of the pollen season. 
Exhaled breath condensate (EBC) was collected immediately before the first and immediately 
after the last injections (t1 and t2), during the pollen season (t3) and after (t4) the pollen season. 
EBC was analyzed to determine the levels of pH and 8-isoprostane. Ten Parietaria-sensitive 
asthmatics served as the untreated control group at t1 and t2.
Results: Measured pH levels were 7.64 ± 0.33 at t1, 7.67 ± 0.23 at t2, 7.72 ± 0.34 at t3, and 
7.82 ± 0.34 at t4 (P = 0.049 vs baseline). 8-isoprostane levels were significantly lower than 
baseline at each visit (mean difference from baseline, for t2: −0.77 pg, P = 0.031; for t3: −0.92 pg, 
P = 0.010; for t4: −0.70 pg, P = 0.048). In the control group, pH levels were 7.73 ± 0.26 at 
baseline and did not change after 6 weeks (7.79 ± 0.25, P = 0.33). Similarly, the concentrations 
of 8-isoprostane in the control group were not different from those of the study group at baseline 
(P = 0.86), and the levels remained unchanged after 6 weeks (P = 0.58).
Conclusion: These findings show that the ultra-short course of vaccine adjuvated with MPL 
acutely reduces the degree of airway inflammation, as expressed by markers of oxidative stress, 
and suggest that this reduction is maintained during and after the pollen season.
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Introduction
The therapeutic approach to allergic asthma is 3-fold: avoidance, medications, 
and immunotherapy. Avoidance of the specific allergen that is responsible for the 
respiratory symptoms, although ideal, is not always possible given that some pollens 
are almost permanently present in the air; on the other hand, the efficacy of allergen 
avoidance may be controversial, as in the case of indoor allergens. Pharmacological 
therapy is used to treat airway inflammation and obstruction. As established by current 
guidelines,1 immunotherapy is advocated as an additional tool in the mildest forms 
of allergic asthma. Immunotherapy has been demonstrated to delay the occurrence of 
worsening asthma,2 to prevent new allergen sensitizations from occurring,3,4 and to 
reduce the frequency and severity of respiratory symptoms.5,6Journal of Asthma and Allergy 2011:4 submit your manuscript | www.dovepress.com
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Two types of immunotherapy have been developed in 
the past and are currently used in clinical practice. The 
subcutaneous allergy injections (SCIT) are administered 
at gradually increasing doses until the maintenance dose is 
attained. Sublingual immunotherapy (SLIT) has been used 
extensively in Europe as an alternative to SCIT. Optimal 
dosing, standardization, and control of the products, and 
allergen modifications such as the introduction of allergoids 
(chemically modified allergens) have drammatically 
improved the safety and tolerability of immunotherapy.
To improve the efficacy of immunotherapy, immunological 
adjuvants have been incorporated in the within allergy 
vaccines. The monophosphoryl lipid A (MPL), a detoxified 
lipopolysaccharide component extracted and purified from 
Salmonella minnesota, has been demonstrated to promote and 
increase the immunological response.7 The new MPL vaccine 
has been demonstrated to be effective in reducing nasal and 
ocular symptom scores, skin test sensitiviy, and medication 
score.8 Little is known, however, about the vaccine’s efficacy 
in treating asthma. Despite the clinical advantages of this 
product,9 the immunological changes following treatment 
have not been fully elucidated. In addition, the changes 
induced by the MPL-adjuvated vaccine on lower airway 
inflammation are not clear. We reasoned that the addition 
of MPL would enhance the anti-inflammatory properties of 
the vaccine. Based on these assumptions, shorter courses 
of immunotherapy have been administered, resulting in 
clinical and functional improvements. However, whether 
these impovements are related to a reduction in the severity 
of airway inflammation is not known. We designed our study 
to assess the role of subcutaneous MPL-adjuvated vaccine 
on features of airway inflammation in intermittent asthmatics 
who were sensitized to Parietaria judaica using the exhaled 
breath condensate (EBC) methodology.
Methods
Subjects
We recruited individuals attending the Allergy Outpatient 
Clinic of the Division of Respiratory Diseases of the 
University of Palermo, Italy, who had received the diagnosis 
of intermittent asthma. The main criteria for inclusion in the 
current study were: 1) skin test positivity only to Parietaria, 
2) no history of any type of specific immunotherapy. Subjects 
who were also sensitized to other allergens or were under 
regular anti-asthmatic treatment were excluded from the study. 
Short-acting β-agonists were withheld for at least 12 hours 
and anti-histamines for 48 hours prior to each evaluation. 
Subjects were tested at least 4 weeks after their most recent 
upper respiratory infection. Ten individuals with intermittent 
asthma who were allergic only to Parietaria served as 
untreated controls. Both the study and the control groups 
received symptomatic therapy for upper and lower respiratory 
symptoms as required. The study was approved by the local 
ethics committee and all subjects gave written, informed 
consent.
Study design
The study had a longitudinal experimental design and 
consisted of three phases. Figure 1 describes the protocol 
and the time-frame of the study. A total of 7 visit days were 
needed to complete the study.
Phase 1
At the first visit (t0), which took place in June and July, all 
inclusion and exclusion criteria were checked and subjects 
were enrolled. The screening evaluation included a 
respiratory questionnaire for both upper and lower airways, 
allergy skin testing to a panel of 10 common aeroallergens, 
and a complete functional assessment. The evaluation of 
the nasal involvement was also performed according to 
the Allergic Rhinitis and its impact on Asthma (ARIA) 
document recommendations.10 Spirometric testing was 
performed with a water-sealed spirometer (Biomedin, 
Padova Italy). Acceptability and reproducibility of FEV1 
and forced vital capacity (FVC) were evaluated based on the 
recommendations of the European Respiratory Society.11
Phase 1 Phase 2 Phase 3
Screening
EBC
Injections
−14 0 1 2 6 22–23 2 6–27 Weeks 
June–July September–October March–April August
Figure 1 Schematic of the protocol that describes the study (see also study design). 
A total of 7 visit days were needed to complete the study. Phase 1 was the screening 
evaluation consisting of lung function assessment and skin prick testing. Phase 2 
consisted of 4 visits at which the study subjects received subcutaneous injections 
of the active product with increasing strength. In the first week (week 0) and the 
last (week 6) the allergy vaccine was injected, and the biological assessment was 
conducted. The untreated control group also participated in this phase. Phase 3 was 
only conducted in the study subjects. in March and April (during pollen season) and 
August (after pollen season) each subject repeated the biological examination.
Abbreviation: eBc, exhaled breath condensate.Journal of Asthma and Allergy 2011:4 submit your manuscript | www.dovepress.com
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Phase 2
During September–October (pre-pollen season), each subject 
visited the laboratory on 4 separate occasions at which time 
they received a subcutaneous injection of the active product 
with increasing strength. The first three 1.0 mL increasing 
strength injections were administered at 1-week intervals, and 
the last top-strength injection was administered at 6 weeks 
from the first injection. At the time of the first (t1) and the last 
(t2) injections of the allergy vaccine, functional and biological 
assessments were conducted. The ultra-short course 
pre-seasonal allergy vaccine (Pollinex® Quattro, Allergy 
Therapeutics, Worthing, England), containing appropriate 
allergoids with MPL, was employed. The vaccine consists of 
purified extract of Parietaria judaica pollen allergen (par j1: 
16.64 µg/mL), which is modified with glutaraldehyde. The 
MPL adjuvant was adsorbed to the L-tyrosine at 50 µg/mL 
in all vaccine dose levels. The 10 asthmatics who served as 
untreated controls underwent EBC collection twice during 
the study at a 6-week interval.
The biological assessment consisted of evaluating 
the inflammatory pattern of the lower airways which was 
established through EBC. EBC was collected (EcoScreen, 
Jaeger, Germany) as the patient breathed room-air through a 
mouthpiece connected to a 2-way non-rebreathing valve and 
to a saliva trap. The valve was connected to an add-on unit 
(ECoVent, Jaeger, Germany), to standardize EBC collection. 
The device (ECoVent) measured breathing volume and the 
procedure was stopped at 120 L of total volume, which 
allowed collection of about 2 mL of condensate from the 
patient in 10 to 15 minutes, depending on the patient’s 
breathing frequency. Each patient was asked to breath at a 
normal frequency and tidal volume wearing a nose clip, after 
rinsing their mouth with water. The collection was performed 
from 09.00 to 14.00 hours in the morning. The collected 
fluid was immediately subdivided into 300 µL aliquots in 
Eppendorf tubes, which were directly transferred to −70°C 
pending analysis.
ph measurement
The EBC pH was measured using a pH-meter with a 
micro-electrode (pH-221 Hanna Instruments, Leighton, 
UK). The pH-meter range was −2.00 to 16.00 with a mean 
resolution/accuracy of the order of 0.01 ± 0.02. A stable 
pH was achieved after de-areation of the EBC specimens 
by bubbling them with nitrogen at 2 bar for 5 minutes.12 
All samples were analyzed together and each sample was 
tested in duplicate.
8-isoprostane measurement
8-Isoprostane concentrations in EBC were measured with a 
specific enzyme immunoassay (EIA) kit (Cayman Chemical, 
Ann Arbor, MI). The antiserum used in the EIA has 100% 
cross-reactivity with 8-isoprostane and 20.6% cross-reactivity 
with prostaglandin F2α (PGF2α), 4% cross-reactivity with 
PGF3α, 1.84% with PGE2 and 1.7% cross-reactivity with PGF1α. 
The detection limit of the assay is 2.7 pg/mL. All samples were 
analyzed together and each sample was tested in duplicate.
Phase 3
As a secondary aim, the biological evaluation performed in 
Phase 2 was repeated in the study group during the pollen 
season (March-April, t3), and after pollen season (August, t4).
Statistical analysis
The pH and the 8-Isoprostane concentrations in the EBC 
represent the outcomes of the study. Data are presented as 
mean ± SD. Treatment-induced changes from baseline over 
time were analyzed by repeated measures one-way ANOVA, 
followed by appropriate post hoc tests. Linear regressions 
were used to examine the relationship between the biological 
variable and indices of lung function before the beginning 
of the treatment. Significance was assumed for two-tailed 
values of P # 0.05.
Results
Phase 1
A total of 20 intermittent asthmatics (M/F: 12/8, age: 
48 ± 10 years) took part in the study. As expected, lung 
function was in the normal range (FEV1/FVC: 0.84 ± 0.02; 
FEV1% predicted: 108% ± 12%). The asthmatics who served 
as the control group (M/F: 5/5), were similar to the study 
group in age (42 ± 8 years, P = 0.76) and in lung function 
characteristics (FEV1/FVC: 0.88 ± 0.01; FEV1% predicted: 
114% ± 9%). Table 1 describes the percentage of subjects 
Table 1 clinical characteristics of subjects belonging to the study 
and the control groups related to the 4 weeks preceding the time 
of recruitment
Study 
group
Control 
group
Upper respiratory symptoms (% of subjects) 40 50
Lower respiratory symptoms (% of subjects) 20 10
Use of short-acting β-agonists (% of subjects) 20 10
Use of antihistamines (% of subjects) 25 15
Note: Data are expressed as percentages of subjects who experienced symptoms 
or required medications.Journal of Asthma and Allergy 2011:4 submit your manuscript | www.dovepress.com
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from both groups who experienced upper and/or lower 
symptoms at the time of recruitment, and who required rescue 
medications. The four asthmatics of the study group and the 
only control subjects who had lower respiratory symptoms 
in the weeks that preceded the beginning of the study were 
also suffering from upper airway symptoms.
Phase 2
None of the volunteers reported any adverse events associated 
with the immunotherapy. During this phase, none of the 
subjects required rescue medications or anti-histamines. 
Treatment with pre-seasonal adjuvated vaccine did not 
significantly change the EBC pH (7.64 ± 0.33 at t1 and 
7.67 ± 0.23 at t2; P = 0.52). In the control group the pH was 
7.73 ± 0.26 and did not change at the following assessment 
performed 6 weeks later (7.79 ± 0.25, P = 0.33). The 
concentrations of 8-isoprostane in the EBC significantly 
dropped immediately after the ultra-short course of allergy 
vaccine (t2): the mean difference from baseline was −0.77 pg 
(P = 0.031). The baseline (t1) and post treatment (t2) values 
for each individual are depicted in Figure 2. In the control 
group, the concentrations of 8-isoprostane were not different 
from those of the study group at baseline (44.1 ± 1.4 pg/mL 
vs 44.4 ± 0.5 pg/mL, P = 0.86; study group vs controls), 
and remained unchanged after 6 weeks (44.6 ± 1.2 pg/mL, 
P = 0.58). This finding lends support to the occurrence of 
the early anti-inflammatory effect of immunotherapy in the 
study group.
The concentrations of 8-isoprostane and pH at t1 were 
not associated with baseline lung function as expressed by 
FEV1% predicted (r = 0.31, P = 0.23 and r = 0.02, P = 0.91, 
respectively).
Phase 3
As a secondary aim, we tested whether changes in markers 
of airway inflammation also occurred in the study subjects 
during and after pollen season. This phase had only an 
exploratory aim, and did not include the control group. 
All study subjects completed the study. Five subjects who 
experienced mild asthma exacerbations during the study, 
presumably due to respiratory viral infections, had their next 
respective assessment postponed for 3 weeks. The EBC pH 
increased in comparison to the baseline values, both at t3 
(7.72 ± 0.34) and t4 (7.82 ± 0.35), reaching a significantly 
higher level only at t4 with respect to baseline (P = 0.049) 
(Figure 3). Remarkably, the 8-isoprostane levels remained 
significantly lower than baseline during the allergy season 
(mean difference from baseline: −0.92 pg, P = 0.010). 
When the collection of EBC was performed outside the 
pollen season (t4), the concentrations of 8-isoprostane 
remained lower than the baseline values (mean difference 
from baseline: −0.70 pg, P = 0.048) (Figure 4). As expected, 
lung function assessed outside pollen season did not differ 
from that recorded at the beginning of the study (FEV1/FVC: 
0.81 ± 0.02; FEV1% predicted: 111% ± 10%, P = 0.81).
Discussion
This is a small study demonstrating that an ultra-short course 
immunotherapy, consisting of 4 pre-seasonal injections with 
pollen allergoids formulated with MPL, exerts early anti-
inflammatory effects, as documented by the significant 
reduction in the levels of 8-isoprostane in the EBC. The 
findings of the study also suggest that the airway inflammatory 
changes are maintained during and after the pollen season. This 
is indicated by the significantly lower levels of 8-isoprostane 
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Figure 2 individual data for the concentrations of 8-isoprostane assessed in the 
exhaled breath condensate of the study subjects. The blue circles represent the 
levels of 8-isoprostane measured before the first injection of the vaccine (t1), and 
the red circles represent the levels of 8-isoprostane measured immediately after the 
last injection of the vaccine (t2). each individual (x axis) is expressed by a blue circle 
and the respective red circle.
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Figure 3 Means (connected circles) for the ph levels that were assessed in the 
exhaled breath condensate of the study subjects. These evaluations were obtained 
at the time of the first (t1) and the last (t2) pre-seasonal injections, during (t3) and 
outside (t4) the pollen season. 
Notes: Symbols indicate statistically significant effects of immunotherapy in post-hoc 
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throughout the period of the study (during and after pollen 
season). These observations provide additional explanations 
for the clinical efficacy of the pre-seasonal immunotherapy.
The pre-seasonal vaccine employed in the current study 
consists of natural allergens combined through a “depot” 
technology to glutaraldehyde-modified pollens in order to 
offer higher tolerability. The immunological response is 
specifically powered by an adjuvant, 3-deacylated mono-
phosphoryl lipid A (MPL), which is a purified, detoxified 
glucolipid extracted from the cell walls of Salmonella 
minnesota R595.13 MPL acts as an agonist of the toll-like 
4 receptors (TLR4), which play a key role in the initial 
immune response against pathogens.14–16 It is plausible to 
speculate that the addition of MPL would account for the 
acute anti-inflammatory effects that were observed in the 
current study. However, the lack of a control group receiving 
vaccine with no MPL does not allow definite conclusions to 
be drawn in this respect.
The main finding of our study is the reduction in airway 
inflammation, as expressed by 8-isoprostane concentrations 
in the EBC, following the ultra-short course of pre-seasonal 
immunotherapy. Isoprostanes are prostaglandin-like com-
pounds formed from the free radical catalysed peroxidation of 
arachidonic acid.17,18 Contrary to the reactive oxygen species, 
which are unstable and short-lived, and as a consequence 
difficult to measure, 8-isoprostane is a stable product of lipid 
peroxidation, and is therefore a reliable marker of oxidative 
stress.19 Increased levels of 8-isoprostane were found in 
EBC of asthmatic subjects, confirming the role of oxidative 
stress in the pathogenesis of asthma.20,21 Recently, Carraro 
and colleagues detected higher levels of 8-isoprostane in 
the EBC of asthmatic children with problematic asthma, 
suggesting that oxidative stress characterizes this asthmatic 
phenotype.22 The concentrations of 8-isoprostane decreased 
after treatment with oral steroids,23 whereas they appear to 
be relatively resistant to inhaled corticosteroids.24,25 To our 
knowledge, this is the first observation of a decrease in 
8-isoprostane concentrations after adjuvated immunotherapy, 
which suggests its anti-inflammatory/antioxidant effects on 
lower airways. As previously stated, it is unclear whether this 
effect is specifically due to the properties of the adjuvant that 
is incorporated in the vaccine. Interestingly, this phenomenon 
occurred immediately after the series of vaccine injections, 
and the reduction persisted throughout pollen season and 
after pollen season. Further studies are needed to explore the 
timing of the immunological response to immunotherapy.
In the present study, we failed to demonstrate correlations 
between 8-isoprostane in EBC and lung function tests. 
This was relatively surprising, since previous observations 
from our group had shown that 8-isoprostane was inversely 
correlated with FEV1% predicted.26 However, these results 
are consistent with previous findings from Montuschi and 
colleagues20 and Zhao and colleagues.27 Discrepancies 
in this correlation are presumably due to differences in 
clinical or demographic characteristics of the study subjects, 
and/or different techniques used for EBC analysis. In the 
current study, inclusion criteria defined the subjects as 
intermittent asthmatics with lung function in the normal 
range; therefore, any significant correlation with indices of 
airway inflammation would seem unlikely.
Many authors have used the assessment of pH in the 
EBC as a measure of airway acidity in association with 
airways inflammation under different conditions. Hunt 
and colleagues demonstrated that EBC from patients with 
acute asthma showed a pH substantially lower than that 
recorded in healthy controls, and the levels of pH in asthma 
normalized with systemic steroid therapy.28 In a recently 
published longitudinal study,29 the acidification of EBC was 
associated with exacerbations of asthma. Furthermore, the 
condensate pH increased along with treatment. Interestingly, 
it has been demonstrated that EBC nitrite levels increase 
after 1-year immunotherapy.30 Hunt and colleagues argued 
that this increase is due to the effect of inhaled corticosteroid 
withdrawal that follows successful immunotherapy. However, 
an alternative hypothesis could be that higher pH levels 
induced by immunotherapy may lead to an increase in EBC 
nitrite, as already observed by Hunt and colleagues.28 In the 
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Figure 4 Means (connected circles) for the concentrations of 8-isoprostane that 
were assessed in the eBc of the study subjects. These evaluations were obtained at 
the time of the first (t1) and the last (t2) pre-seasonal injections, during (t3) and after 
(t4) the pollen season. 
Notes: Symbols indicate statistically significant effects of immunotherapy in post hoc 
analyses: *P = 0.031, t2, vs baseline; P = 0.010, t3 vs baseline; P = 0.048, t4 vs baseline.
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current study, changes in the pH were small and not significant, 
except at the end of the study (after pollen season).
The study has several limitations. First, we included 
a control group that did not undergo a placebo treatment, 
nor were they followed during or after the pollen season. 
This limits the conclusions of the study. Indeed, the lack of 
a placebo injection, ie, administration of vaccine   without 
MPL adjuvant, does not allow for definite conclusions 
on the contribution of the adjuvant to the efficacy of the 
  vaccine. In addition, the lack of a control group during and 
outside the pollen season can only suggest, but not prove, 
that the pre-seasonal vaccine has a long-lasting effect on 
markers of airway inflammation. Second, we acknowledge 
that the EBC collection merits standardization so that its use 
in clinical practice is no longer a limitation.
The allergy vaccine containing MPL has been demon-
strated to be safe and well-tolerated. Many studies involving 
MPL have shown a lack of toxic effects.8,9,31 From a clinical 
standpoint, efficacy of the Th-1 adjuvated vaccine has largely 
been demonstrated.8,9,32 It is logical to speculate that the 
requirement of only 4 pre-seasonal injections to achieve a 
satisfactory clinical response in terms of nasal, ocular, and 
bronchial symptoms is expected to dramatically improve 
adherence to treatment. In conclusion, our study indicates that 
the pre-seasonal adjuvated vaccine exerts acute inflammatory 
changes in the airways of allergic asthmatics. These findings 
could contribute to further explanation of the clinical benefit 
of the ultra-short pre-seasonal vaccine.
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